Biotechnology Company Mithradote Bio Secures $1 Million Seed Round for Self-Administered Antidote Development

Mithradote Bio secures an oversubscribed $1 million seed round to develop a novel self-administered antidote against 'date-rape' drugs. CEO emphasizes the need for a self-administered solution for drug-facilitated sexual assault. Taho Pharma and Vickers Venture Partners express their support for this meaningful program.